Blar i St. Olavs hospital på tidsskrift "Circulation. Genomic and precision medicine"
Viser treff 1-1 av 1
-
Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition
(Peer reviewed; Journal article, 2019)PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, ...